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Abstract
Background: Inflammation plays a key role in the pathogenesis of acute myocardial infarction (MI). However, it is unclear
whether marker of immune activation will provide prognostic information in these patients. We hypothesized that
circulating levels of soluble CD93 (sCD93), a soluble form of transmembrane glycoprotein CD93, is increased in acute MI
patients and its level would be associated with clinical outcomes in patients with acute MI.
Methods: We measured circulating levels of sCD93 in 120 patients with acute MI (63613 yrs, M:F = 85:35) and in 120 age,
sex-matched control subjects. In patients with acute MI, clinical characteristics, echocardiographic and laboratory findings
were assessed at the time of initial enrollment. The primary outcome was defined as all-cause and cardiovascular death.
Results: Circulating sCD93 levels were significantly higher in patients with acute MI than in control subjects (552.16293.7 vs.
429.86114.2 ng/mL, p,0.0001). Upon in vitro inflammatory stimulation, increased CD93 shedding was demonstrated in
acute MI patients but not in control subjects. During follow up period (median 208 days, 3-1058 days), the primary outcome
occurred in 18 (15%) patients (9 cardiovascular deaths). Circulating levels of sCD93 were associated with all cause (p,
0.0001) and cardiovascular (p,0.0001) mortality in patients with acute MI. Multivariate Cox regression analysis revealed that
initial sCD93 level was found to be an independent predictor of all cause (p = 0.002) and cardiovascular mortality (p = 0.033)
when controlled for age and left ventricular ejection fraction.
Conclusions: Circulating levels of sCD93 are elevated in patients with acute MI and their levels were associated with adverse
clinical outcomes.
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Introduction
Myocardial infarction (MI) is defined as a clinical event caused
by coronary thrombosis, and subsequent myocardial ischemia in
which there is evidence of myocardial injury or necrosis [1]. Two
major causes of coronary thrombosis are plaque rupture and
endothelial erosion [2,3]. Recent studies have shown that
inflammation plays a key role in the pathogenesis of both plaque
rupture and endothelial erosion. Activated immune cells produce
various inflammatory molecules and proteolytic enzymes that can
weaken the fibrous cap and activate cells in the core, transforming
the stable plaque into a vulnerable, unstable structure that can
rupture, induce a thrombus, and elicit an acute myocardial
infarction. Because inflammation plays a key role in the
pathogenesis of acute MI, a relevant biomarker of immune
activation may provide novel prognostic information in these
patients.
CD93 is a 68 kDa transmembrane glycoprotein and is
expressed in monocytes, leukocytes, and endothelial cells. CD93
is over-expressed upon inflammatory stimulation, and the soluble
form (sCD93) is known to be increased in various inflammatory
conditions [4–6]. It has been shown that sCD93 induces the
differentiation of monocytes into macrophage-like cells that have
increased phagocytic activities and enhanced cell adhesion, and it
has been implicated in inflammation and inflammatory diseases
such as rheumatoid arthritis [6].
A recent study demonstrated that CD93 is correlated with the
risk of coronary artery disease (CAD) [7–9]. In a genetic
replication study, van der Net et al. [8] reported that patients
homozygous for the T-allele of the CD93 genetic polymorphism
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had a 26% increased risk of CAD compared with patients with at
least one C-allele (p = 0.01). Significant associations between
plasma sCD93 levels, premature MI, and the incidence of CAD
were reported in two independent cohorts [9]. Also, it has been
demonstrated that the minor allele of an single nucleotide
polymorphism (SNP) in the 39 untranslated region of the CD93
gene was associated with increases in both plasma sCD93
concentration (p= 0.03) and CD93 mRNA expression levels in
peripheral blood mononuclear cells (p = 0.02). These data suggest
that genetic polymorphisms of CD93 and circulating sCD93 levels
are associated with CAD in cross-sectional studies.
However, the relationship between sCD93 and the prognosis of
acute MI has never been investigated. Therefore, in the present
study, we examined if the circulating level of sCD93 is increased in
acute MI patients. In addition, to explore the possible underlying
mechanism leading to increased sCD93, we compared the
shedding of CD93 in monocytes between patients with acute MI
and control subjects. Finally, we investigated the impact of
circulating sCD93 levels on clinical outcomes in acute MI patients.
Methods
Study population
One hundred twenty patients who were diagnosed with acute
MI at Severance Cardiovascular Hospital were enrolled. MI was
defined as: 1) typical continuous chest pain for more than 30 min,
2) ST segment elevation of more than 0.1 mV in two or more
successive leads or ST segment depression of more than 0.2 mV in
two or more successive leads monitored by a standard 12 lead
electrocardiogram, 3) either a rise of creatinine kinase-MB to
greater than twice the normal level or an elevation of troponin T
of $0.1 ng/mL. Patients underwent a complete physical exam-
ination, baseline electrocardiogram, and laboratory assessment at
the time of initial enrollment. Serum sampling for the analysis of
sCD93 was done at the morning following the admission. Patients
with a history of overt chronic inflammatory diseases such as
rheumatoid arthritis or autoimmune disease and/or those on anti-
inflammatory medications were excluded from this study.
Age and gender-matched, healthy control subjects (n = 120)
were randomly selected from volunteers who were voluntarily
enrolled in the Yonsei Cardiovascular Genome Center. All control
subjects had no symptoms or history of coronary artery disease,
and had a normal baseline electrocardiogram.
Ethics Statement
The study protocol was approved by the institutional review
board (IRB) of Yonsei University College of Medicine and IRB
number was 4-2004-0103. All subjects provided written informed
consent to participate in this study.
Sandwich enzyme-linked immunosorbent assay (ELISA)
for sCD93
A 96-well micro assay plate was coated with mouse anti-human
CD93 Ab (1 mg/mL, R&D systems, Minneapolis, MN) and then
blocked with 3% skim milk. Human sera from either acute MI
patients or healthy control subjects were added and incubated for
2 h. After washing, the plate was incubated with goat anti-mouse
CD93 Ab (0.5 mg/mL, R&D systems) for 1 h. Subsequently, the
plate was incubated with anti-goat IgG-horseradish peroxidase
(HRP) for 1 h. After washing, the plate was colorimetrically
developed with o-phenylenediamine dihydrochloride substrate
(Sigma-Aldrich, St. Louis, MO), and absorbance was read with
the VERSAmax tunable microplate reader (Molecular Devices,
Toronto, Ontario, Canada). Recombinant human sCD93 (amino
acid 24–552) fused with human IgG1 Fc was used as a standard
molecule as previously described [6]. To avoid inter-observer
variability, a single investigator blinded to the clinical variables
and laboratory findings executed the sandwich ELISA experi-
ments. Intra- and inter-assay coefficients of variation (CVs) were
1.7% and 6.3%, respectively.
In vitro analysis for shedding of sCD93 from monocytes
Peripheral blood mononuclear cells were isolated from the
venous blood of six acute MI patients or six age and gender-
matched healthy control subjects by Ficoll-density gradient.
Monocytes were isolated by CD14 magnetic beads (Miltenyi
Biotec, Auburn, CA). The purity of the isolated monocytes was
92–97% in flow cytometry analysis with anti-CD14-APC Ab (BD
Biosciences, San Jose, CA). The isolated monocytes were
incubated with or without lipopolysaccharide (LPS) (5 mg/mL)
for 24 h, and sCD93 levels were analyzed by sandwich ELISA in
the culture supernatants.
Statistical analysis
Continuous variables were presented as a mean6SD. Categor-
ical variables were expressed as a percentage of the group total.
Discrete variables were compared using the chi-squared method,
and independent t-tests were used for continuous variables.
Regarding the cut-off value of the sCD93 for cumulative
mortality, we decided cut-off point according to Youden index, for
all cause mortality, natural logarithm (Ln) sCD93 6.48 (sensitivity
61.1% and specificity 87.3%) and for CV mortality, Ln sCD93
6.38 (sensitivity 88.9% and specificity 78.4%). The cumulative
incidence of mortality was estimated using the Kaplan-Meier
method. The significance of the curves was tested using the log-
rank test.
Univariate and multivariate Cox regression analysis were
performed to identify independent predictors of all-cause and
cardiovascular death. Because of relatively low mortality rate
(n = 18 of 120), three different models were made based on
goodness of fit. Age, sCD93, and high sensitivity C-reactive
protein (hsCRP) were the variables used for the best-fit model for
all-cause mortality, while sCD93, age, and LVEF were those used
in the best-fit model for cardiovascular mortality. To verify the
effect of sCD93 in these models, a likelihood ratio (LR) chi-square
test was done to compare the reduced model (model without
sCD93) and the full model (model with sCD93).
Statistical analyses were performed using R package, version
3.0.2 (http://www.R-project.org) and statistical significance was
defined as p,0.05.
Results
Circulating sCD93 levels in acute MI patients
Baseline clinical characteristics and laboratory findings are
summarized in table 1 and detailed characteristics of acute MI
patients are summarized in table 2. Circulating sCD93 levels were
significantly higher in patients with acute MI than in control
subjects (552.16293.7 ng/mL vs. 429.86114.2 ng/mL, p,
0.0001). Patients with Non-ST elevation MI showed higher
sCD93 levels when compared with those of patients with ST
elevation MI (625.66364.9 ng/mL vs. 491.96203.0 ng/mL,
p= 0.018). However, circulating sCD93 levels were not signifi-
cantly different according to culprit artery (left main artery, left
anterior descending artery, left circumflex artery and right
coronary artery) or CAD extent. There was no significant
correlation between sCD93 levels and hsCRP or peak cardiac
enzyme in this study, showing a relatively different character of
sCD93 in Acute MI
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sCD93 as an inflammation marker. We also evaluated surface
expression levels of CD93 in peripheral monocytes of 51 patients
with acute MI whose peripheral blood mononuclear cells (PBMCs)
were available. There was no significant correlation between
surface expression level of CD93 in monocytes and the circulating
level of sCD93. These results reveal that circulating sCD93 levels
are selectively increased in patients with acute MI, regardless of
the surface expression level of CD93 in peripheral monocytes.
Increased shedding of sCD93 from monocytes in acute
MI patients
To reveal the underlying mechanism of increased sCD93 in
acute MI patients, we investigated shedding of CD93 in monocytes
of acute MI patients and also in healthy control subjects with or
without LPS. LPS is a well-known toll-like receptor stimulator
which may mimic the inflammatory condition of acute MI.
Without LPS stimulation, there was no difference between the
level of sCD93 in monocytes of acute MI patients and control
subjects. However, the amount of sCD93 in monocytes of acute
MI patients with LPS stimulation was significantly higher than
that of acute MI patients without LPS stimulation (12.760.9 vs.
11.161.0 ng/mL, respectively, p = 0.002, figure 1). There was no
change of sCD93 in healthy control subjects with or without LPS
stimulation 11.160.8 vs. 11.061.6 ng/mL, respectively,
p = 0.921). Therefore, monocytes of acute MI patients showed
increased susceptibility of CD93 shedding upon inflammatory
stimulation when compared with that of healthy control subjects.
Relationship of circulating sCD93 levels with clinical
outcomes of acute MI patients
We evaluated whether the increased level of sCD93 is associated
with clinical outcomes in acute MI patients. During the follow-up
period (median 208 days), the primary outcome, which was
defined as all-cause and cardiovascular death, had occurred in 18
(15%) patients (9 cardiovascular deaths). When the patients with
acute MI were divided by level of sCD93 according to Youden
index, circulating levels of sCD93 were shown to be associated
with all-cause (p,0.001) and cardiovascular (p,0.001) mortality
(figure 2). Hosmer and Lemeshow analysis for all cause mortality
(P=0.2972) and CV mortality (P=0.6841) showed acceptable
calibration (P.0.05), which means good agreement between
observed outcomes and predictions. Because of the relatively low
rate of mortality (15%), three different models were made based on
the goodness of fit. Age, sCD93, and hsCRP were the variables of
the best fit model for all-cause mortality and sCD93, age, and
LVEF were those of the best fit model for cardiovascular mortality.
Multivariate Cox regression analysis revealed that the initial
sCD93 level was an independent predictor of both all-cause
(p = 0.005) and cardiovascular mortality (p = 0.033) when con-
trolled for age and hsCRP or age and LVEF, respectively (table 3).
The likelihood ratio chi-square test revealed that the sCD93 level
was a significant variable in these models (Model 1, P=0.003;
Model 2, P,0.001; Model 3, P,0.001 for all-cause mortality,
Model 1, P=0.03; Model 2, P=0.005; Model 3, P,0.001 for
cardiovascular mortality).
Discussion
In this study, we demonstrated that circulating levels of sCD93
are increased in patients with acute MI. In addition, monocytes
isolated from acute MI patients show increased shedding of CD93
upon inflammatory stimulation, suggesting possible mechanism for
the elevated sCD93 in these patients. Finally, we also showed that
elevated levels of sCD93 were associated with adverse clinical
outcomes in patients with acute MI.
The relationship between CD93 and CAD has been docu-
mented in previous genetic association studies [7,8]. Ma¨larstig et
al. [9] reported on the relationship between plasma levels of
sCD93 and the risks of both premature MI and CAD in two
independent cohorts. However, this study was a cross-sectional
association study without prognostic implication. The present
study is important because it is the first study to demonstrate the
Table 1. Clinical characteristics and laboratory findings of analyzed subjects.
Acute MI (N=120) Control (N=120) p-value*
Age (years) 62.6612.8 60.2612.9 0.139
Male (%) 85 (70.8%) 85 (70.8%) -
Hypertension (%) 73 (60.8%) 18 (15.0%) ,0.001
DM (%) 42 (35.0%) 5 (4.2%) ,0.001
Hemoglobin (g/dL) 13.462.3 14.361.6 0.001
T. chol (mg/dL) 170.5652.2 197.0630.8 ,0.001
TG (mg/dL) 122.8675.7 137.9686.2 0.155
HDL (mg/dL) 39.0610.6 49.0612.9 ,0.001
LDL (mg/dL) 101.7639.9 120.46.28.1 ,0.001
FBS (mg/dL) 186.46121.2 87.3618.5 ,0.001
BUN (mg/dL) 19.8610.4 15.364.2 ,0.001
Creatinine (mg/dL) 1.461.3 0.860.2 ,0.001
Uric acid (mg/dL) 5.461.8 5.261.4 0.209
hsCRP (mg/L) 27.4659.7 2.268.3 ,0.001
sCD93 (ng/mL) 552.16293.7 429.86114.2 ,0.001
Values are presented as n (%) or mean 6 SD. DM, diabetes mellitus; T. chol, Total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; FBS, fasting blood sugar; BUN, blood urea nitrogen; hsCRP, high sensitive C-reactive protein; sCD93, soluble CD93.
*p-value ,0.05 is considered significant.
doi:10.1371/journal.pone.0096538.t001
sCD93 in Acute MI
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association between increased levels of sCD93 and clinical
outcomes in patients with acute MI.
We observed an early divergence of the Kaplan-Meier curves
shortly after the diagnosis of acute MI. Activation of chronic
inflammation might be related with early adverse event after the
acute MI, however the cause and effect relationship between
inflammation and early adverse prognosis is not clear yet. There
are no known relevant biomarkers of immune activation in
atherosclerotic plaque rupture. hsCRP is the most extensively
studied biomarker of inflammation in cardiovascular diseases.
However, the prognostic value of hsCRP in patients with acute MI
is controversial. Some studies have found that serum hsCRP
predicts the risk of 30-day or long-term mortality after an MI
[10,11]. However, other reports have found no such relationship
[12]. In this study, we have shown that the predictive prognostic
value of sCD93 was independent of hsCRP in patients with acute
MI.
Relationship between increased levels of sCD93 and adverse
clinical outcomes in patients with acute MI might be explained by
the underlying pathophysiology of atherosclerosis. Monocyte plays
a key role from the beginning of the atherosclerotic plaque
development to the final plaque rupture eliciting an acute MI.
Circulating monocytes are recruited into the activated endothe-
lium of artery and then differentiate into macrophage, which
comprises major cellular component of atherosclerotic plaque.
With the progression of atherosclerotic plaque, activated macro-
phage produces various pro-inflammatory cytokines, proteases,
free oxygen radicals and vasoactive molecules that can destabilize
the lesions. All these molecules might induce the activation and
rupture of atherosclerotic plaque, thrombosis, and subsequently an
acute MI [2,3]. A recent study showed that sCD93 induced
differentiation of monocytes to macrophage like cells, as evidenced
by activated cell adhesion and increased phagocytic activities. In
addition, this differentiation resulted in increased pro-inflamma-
tory cytokine production [6]. The link between sCD93 and
Table 2. Laboratory, angiographic, echocardiographic findings and treatment modalities of AMI patients.
Characteristics Values
Laboratory findings
Initial CK-MB (ng/mL) 31.5662.0
Peak CK-MB (ng/mL) 143.76165.0
Initial Troponin-T (ng/mL) 1.062.3
Peak Troponin-T (ng/mL) 1.763.1
NT-proBNP (pg/mL) 4676.169475.3
Culprit artery
Left main 1 (0.8%)
LAD 50 (41.6%)
LCx 14 (11.7%)
RCA 46 (38.3%)
Angiography not done 9 (7.5%)
Echocardiographic data
LVEF (%) 47.3613.0
LVEDD (mm) 51.466.1
LVESD (mm) 38.167.4
LV mass index (g/m2) 106.0626.6
LA Vol. index (ml/m2) 28.9611.6
Types of treatment
PCI 96 (80%)
CABG 7 (5.8%)
Medical treatment only 17 (14.2%)
Types of medication
Aspirin 119 (99.2%)
Clopidogrel 114 (95.0%)
ACEi/ARB 102 (85.0%)
Beta-blocker 104 (86.7%)
Spironolactone 20 (16.7%)
CCB 23 (19.2%)
Statin 114 (95%)
Values are presented as a %, or mean 6 SD; CK-MB, creatine kinase MB; NT-proBNP, N-terminal pro-brain natriuretic peptide; LAD, left anterior descending artery; LCx,
left circumflex artery; RCA, right coronary artery; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end
systolic dimension; LV mass index, left ventricular mass index; LA Vol. index, left atrial volume index; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockade; CCB, calcium channel blocker.
doi:10.1371/journal.pone.0096538.t002
sCD93 in Acute MI
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monocyte activation has been implicated in inflammation and
circulating levels of sCD93 can be a maker of monocyte activation.
In this study, we have demonstrated that circulating sCD93, novel
monocyte inflammatory marker, are elevated in patients with
acute MI and their levels were associated with adverse clinical
outcomes.
The mechanism underlying elevated sCD93 levels in patients
with acute MI might be an increased shedding of CD93 from
monocytes in these patients. The lack of either a negative or
positive correlation between CD93 expression in monocytes and
the circulating level of sCD93 may suggest tight homeostatic
control of CD93 expression in monocytes even during the
inflammatory process. The fact that monocytes of acute MI
patients showed increased susceptibility of CD93 shedding upon
inflammatory stimulation suggest that differential response to
inflammatory stimuli may underlie the reason why circulating
sCD93 levels are increased in patients with acute MI. Detailed
studies of the underlying mechanisms of and genetic influences on
CD93 shedding in the physiological environment and its relevance
to CAD need to be conducted.
The present study has several potential limitations. First, the
differential power of circulating sCD93 concentration between
patients with acute MI and control subjects is relatively low.
Therefore, the cutoff value for the normal range of sCD93 cannot
be determined in this study. This low differential power of
circulating sCD93 may be related to the systemic origin of CD93
shedding. Increased level of sCD93 in patients with acute MI
cannot be attributed to CAD-specific inflammation. Rather, it
may represent an overall increase in the monocyte inflammatory
burden. In addition, circulating sCD93 levels were studied only
once at the acute stage without serial measurements.
Second, the primary outcome, which was defined as all-cause
and cardiovascular death, had occurred in only 18 (15%) patients
(nine cardiovascular deaths and nine non-cardiovascular deaths).
This small number of primary outcomes prohibited the use of all
significant variables in our multivariate analysis. Only two or three
variables including sCD93 were able to be used. However, we
used three different models based on goodness of fit to explore the
clinical value and implications of sCD93 in patients with acute MI.
Even after adjusting for the most well-known prognostic factors,
age and LVEF, the initial sCD93 level was found to be an
independent predictor of all-cause and cardiovascular mortality.
Third, we could not measure other inflammation markers such as
neopterin in this study. We only measured sCD93, hsCRP and
cardiac enzymes. There was no significant correlation between
sCD93 levels and hsCRP or peak cardiac enzyme in this study,
showing a relatively different character of sCD93 as an
inflammation marker. Finally, it is difficult to determine whether
elevated sCD93 is the result or the cause of acute MI. Increased
sCD93 levels may be related with the pathogenesis of acute MI,
however further investigations are needed to identify the direct
cause and effect relationship.
Figure 2. Cumulative Kaplan–Meier estimates of all cause and cardiovascular mortality according the circulating levels of sCD93.
doi:10.1371/journal.pone.0096538.g002
Figure 1. Increased amount of sCD93 in supernatant after LPS
stimulation in acute MI patients.
doi:10.1371/journal.pone.0096538.g001
sCD93 in Acute MI
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Conclusions
In the present study, we have demonstrated that circulating
levels of sCD93 are increased in patients with acute MI.
Monocytes isolated from acute MI patients show increased
shedding of CD93 upon inflammatory stimulation, suggesting
possible mechanism for the elevated sCD93 in these patients.
Finally, we also showed that elevated levels of sCD93 were
associated with adverse clinical outcomes in patients with acute
MI. Circulating sCD93 as a marker of monocyte inflammation
might be considered for risk stratification in patients with acute MI
and needs to be further studied to more completely understand the
inflammatory pathophysiology of this disease process.
Author Contributions
Conceived and designed the experiments: J-CY E-CS J-WH. Performed
the experiments: J-CY HTY J-WJ Y-BP. Analyzed the data: J-CY HTY J-
WJ HSL YJ YWP Y-BP E-CS J-WH. Contributed reagents/materials/
analysis tools: J-CY HTY J-WJ YJ YWP Y-BP. Wrote the paper: J-CY
HTY E-CS J-WH.
References
1. Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction
redefined—a consensus document of The Joint European Society of Cardiol-
ogy/American College of Cardiology Committee for the redefinition of
myocardial infarction. J Am Coll Cardiol 36: 959–969.
2. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease.
N Engl J Med 352: 1685–1695.
3. Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from
pathophysiology to practice. J Am Coll Cardiol 54: 2129–2138.
4. Bohlson SS, Silva R, Fonseca MI, Tenner AJ (2005) CD93 is rapidly shed from
the surface of human myeloid cells and the soluble form is detected in human
plasma. J Immunol 175: 1239–1247.
5. Greenlee MC, Sullivan SA, Bohlson SS (2009) Detection and characterization of
soluble CD93 released during inflammation. Inflamm Res 58: 909–919.
6. Jeon JW, Jung JG, Shin EC, Choi HI, Kim HY, et al. (2010) Soluble CD93
induces differentiation of monocytes and enhances TLR responses. J Immunol
185: 4921–4927.
7. Shiffman D, Kane JP, Louie JZ, Arellano AR, Ross DA, et al. (2008) Analysis of
17,576 potentially functional SNPs in three case-control studies of myocardial
infarction. PLoS One 3: e2895.
8. van der Net JB, Oosterveer DM, Versmissen J, Defesche JC, Yazdanpanah M,
et al. (2008) Replication study of 10 genetic polymorphisms associated with
coronary heart disease in a specific high-risk population with familial
hypercholesterolemia. Eur Heart J 29: 2195–2201.
9. Malarstig A, Silveira A, Wagsater D, Ohrvik J, Backlund A, et al. (2011) Plasma
CD93 concentration is a potential novel biomarker for coronary artery disease.
J Intern Med 270: 229–236.
10. Suleiman M, Aronson D, Reisner SA, Kapeliovich MR, Markiewicz W, et al.
(2003) Admission C-reactive protein levels and 30-day mortality in patients with
acute myocardial infarction. Am J Med 115: 695–701.
11. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, et al. (2006) Early
inflammation and risk of long-term development of heart failure and mortality in
survivors of acute myocardial infarction predictive role of C-reactive protein.
J Am Coll Cardiol 47: 962–968.
12. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, et al. (2004) B-
type natriuretic peptide at presentation and prognosis in patients with ST-
segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am
Coll Cardiol 44: 335–339.
sCD93 in Acute MI
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e96538
